Advertisement

Banner Biovision 2014 Lyon France June 600x60px
Document › Details

Molzym GmbH & Co. KG. (2/11). "Press Release: Researchers Identifiy Non-culturable Microbes from Bloodstream Infections".

Organisation Organisation Molzym GmbH & Co. KG
  Group Kompass (Group)
Products Product SelectNA™ pathogen detection system
  Product 2 DNA test, indication
Index term Index term Kompass–NorDiag: sample preparation technology, 200810– collab integration into Molzym's molecular diagnostics products
Person Person Lorenz, Michael (Univ Bremen + Molzym)
     


Molzym, a German molecular diagnostic company has developed in collaboration with NorDiag ASA the first automated platform worldwide for the culture-independent universal identification of microorganisms from whole blood and is now launching the system.

Clinical studies have shown that a high proportion of microbial infections are not detectable by conventional growth culture. Microbial growth in culture media can be inhibited by antibiotic pretreatment and complex microbial nutrition requirements. A group of researchers from the Institute of Medical Microbiology, Ulm, Germany recently have shown in a study on culture-independent broad-range identification of microbes from bloodstream, synovial fluid and CSF infections that up to 63% of infections are culture negative. Conventional culturing of bacterial and fungal infections can take up to seven days for identification of the organism. Nosocomial infections and antibiotic resistances have dramatically increased in recent years, and there is increased demand in the hospitals for rapid, sensitive, culture-independent identification technologies.

Generally, molecular identification can help filling the dangerous gap of culture-negative infections (CNI). Because infections are caused by a broad-range of pathogens, molecular technologies that enable the verification of any microbial strain from clinical specimens are demanded. Today, Molzym, a German molecular diagnostic company has launched the first automated platform worldwide for the culture-independent universal identification of microorganisms from whole blood.

"We have validated our molecular system for more than 345 microbial species now, says Michael Lorenz, CEO of Molzym. Jan Detmers, Director Marketing & Sales at Molzym adds: "The automation of our platform enables results within only 4 hours. This approaches closely what hospitals expect for timely clinical decision making and therapy monitoring".


About Molzym:

Molzym, headquartered in Bremen, Germany, is a manufacturer of innovative products for molecular diagnostics. Molzym's diagnostic products focus on proprietary technologies for the selective isolation of pathogen DNA from various clinical specimens. The new automation platform, SelectNA™, allows for up to 40,000-fold better PCR sensitivity as compared to conventional DNA-isolation protocols. The system therefore enables culture-independent direct testing of blood and supports the universal detection of pathogens causing culture negative infections. For further information - www.molzym.com

Press contact:
Jan Detmers,
Phone: +49 421-696162-0
E-mail: info@molzym.com


About NorDiag:

NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and is the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The company has offices and laboratories in Stockholm, Sweden, in West Chester (PA), USA and in Vienna, Austria. The group has today 40 man-labour years. NorDiag is listed on Oslo Stock Exchange with ticker NORD. For further information - www.nordiag.com

Press contact:

Contact:
CEO Mårten Wigstøl
Phone. +47 911 65775

   
Record changed: 2011-11-25

Advertisement

Banner BIO Deutschland CFO Summit 2014 Berlin May 600x60px

More documents for Kompass (Group)


To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Banner BIO Deutschland CFO Summit 2014 Berlin May 600x60px




» top

Advertisements

Banner EBD Group BIO Europe 2013 BEU Frankfurt November 120x180px Banner BIO Deutschland CFO Summit 2014 Berlin May 120x120px Banner Biovision 2014 Lyon France June 120x80px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Banner [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px